Abpro Holdings (ABPO) Long-Term Investments (2022 - 2024)
Abpro Holdings' (ABPO) quarterly Long-Term Investments came in at $1.4 million in Q3 2024, down 96.1% YoY from $36.5 million in Q4 2023, and down 81.32% on a QoQ basis from $7.6 million in Q2 2024.
Abpro Holdings (ABPO) Long-Term Investments (2022 - 2024) Analysis & Trends
Abpro Holdings (ABPO) has 3 years of Long-Term Investments data on file, last reported at $1.4 million in Q3 2024.
- Quarterly Long-Term Investments fell 96.1% year-over-year to $1.4 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.4 million (down 96.1% YoY) and the FY2023 annual result came in at $29.7 million, changed N/A from the prior year.
- Long-Term Investments fell to $1.4 million in Q3 2024, from $7.6 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $313.1 million in Q1 2023 to a low of $1.4 million in Q3 2024.
- A 3-year average of $135.1 million and a median of $36.2 million in 2023 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2023 — Long-Term Investments grew 2.37% — and 2024, when it slumped 97.6%.
- Tracing ABPO's Long-Term Investments over 3 years: stood at $307.5 million in 2022, then sank by 90.33% to $29.7 million in 2023, then plunged by 95.21% to $1.4 million in 2024.
- The last three Long-Term Investments figures came in at $1.4 million (Q3 2024), $7.6 million (Q2 2024), and $7.5 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 7.62 Mn |
| Mar 31, 2024 | 7.51 Mn |
| Dec 31, 2023 | 29.73 Mn |
| Sep 30, 2023 | 36.47 Mn |
| Jun 30, 2023 | 36.00 Mn |
| Mar 31, 2023 | 313.07 Mn |
| Sep 30, 2022 | 307.55 Mn |
| Jun 30, 2022 | 306.07 Mn |
| Mar 31, 2022 | 305.83 Mn |